Advances in Cardiovascular Pharmacotherapy. VI. Sacubitril-Valsartan, An Angiotensin Receptor-Neprilysin Inhibitor.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Advances in Cardiovascular Pharmacotherapy. VI. Sacubitril-Valsartan, An Angiotensin Receptor-Neprilysin Inhibitor.
- Published In:
- Journal of cardiothoracic and vascular anesthesia, 40(3), 960-984 (2026)
- Authors:
- Pagel, Paul S, Hang, Dustin, Freed, Julie K, Crystal, George J
- Database ID:
- RPEP-15843
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15843APA
Pagel, Paul S; Hang, Dustin; Freed, Julie K; Crystal, George J. (2026). Advances in Cardiovascular Pharmacotherapy. VI. Sacubitril-Valsartan, An Angiotensin Receptor-Neprilysin Inhibitor.. Journal of cardiothoracic and vascular anesthesia, 40(3), 960-984. https://doi.org/10.1053/j.jvca.2025.12.003
MLA
Pagel, Paul S, et al. "Advances in Cardiovascular Pharmacotherapy. VI. Sacubitril-Valsartan, An Angiotensin Receptor-Neprilysin Inhibitor.." Journal of cardiothoracic and vascular anesthesia, 2026. https://doi.org/10.1053/j.jvca.2025.12.003
RethinkPeptides
RethinkPeptides Research Database. "Advances in Cardiovascular Pharmacotherapy. VI. Sacubitril-V..." RPEP-15843. Retrieved from https://rethinkpeptides.com/research/pagel-2026-advances-in-cardiovascular-pharmacotherapy
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.